Alexion Not Scared Of Amgen Biosimilar Threat To Soliris
Companies Settled Eculizumab Litigation In US Earlier This Year
Executive Summary
Alexion Pharmaceuticals is confident of its strategy to switch patients from Soliris to Ultomiris as the threat of biosimilar competition to the former looms. But launching a biosimilar to Soliris alone will be a challenge, the company maintains.
You may also be interested in...
Amgen’s Mvasi Biosimilar Overtakes Avastin In The US
Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.
Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025
Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.
Amgen Chooses To Settle In US Soliris IPR Tussle
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.